サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1369035

世界の乳幼児・小児用混合ワクチン市場：考察と予測 (2029年まで)

Global Infant and Child Multiple Vaccine Market Insights, Forecast to 2029
出版日: | 発行: QYResearch | ページ情報: 英文 90 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
世界の乳幼児・小児用混合ワクチン市場：考察と予測 (2029年まで)
出版日: 2023年10月27日
発行: QYResearch
ページ情報: 英文 90 Pages
納期: 2～3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、乳幼児・小児用混合ワクチン (Infant and Child Multiple Vaccine) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査対象

  • 乳幼児・小児用混合ワクチンの製品概要
  • 市場：タイプ別
    • 世界の乳幼児・小児用混合ワクチンの市場規模成長率：タイプ別, 2018 VS 2022 VS 2029
    • Pentavalent Vaccine
    • Quadruple Vaccine
    • Triple Vaccine
    • Others
  • 市場：用途別
    • 世界の乳幼児・小児用混合ワクチンの市場規模成長率：用途別, 2018 VS 2022 VS 2029
    • 12 Months Below
    • 12 Months Above
  • 前提条件と制限
  • 調査目的
  • 対象期間

第2章 レポート概要

  • 世界の乳幼児・小児用混合ワクチン売上予測・予想 2018-2029
  • 世界の乳幼児・小児用混合ワクチンの収益：地域別
    • 世界の乳幼児・小児用混合ワクチンの収益：地域別: 2018 VS 2022 VS 2029
    • 世界の乳幼児・小児用混合ワクチンの収益：地域別 (2018-2023)
    • 世界の乳幼児・小児用混合ワクチンの収益：地域別 (2024-2029)
    • 世界の乳幼児・小児用混合ワクチンの収益市場シェア 地域別 (2018-2029)
  • 世界の乳幼児・小児用混合ワクチン売上予測・予想 2018-2029
  • 世界の乳幼児・小児用混合ワクチンの販売：地域別
    • 世界の乳幼児・小児用混合ワクチンの販売：地域別: 2018 VS 2022 VS 2029
    • 世界の乳幼児・小児用混合ワクチンの販売：地域別 (2018-2023)
    • 世界の乳幼児・小児用混合ワクチンの販売：地域別 (2024-2029)
    • 世界の乳幼児・小児用混合ワクチンの販売市場シェア 地域別 (2018-2029)
  • 米国・カナダ
  • 欧州
  • 中国
  • アジア（中国を除く）
  • 中東, アフリカ ・ラテンアメリカ

第3章 競合：企業別

  • 世界の乳幼児・小児用混合ワクチンの販売：企業別
    • 世界の乳幼児・小児用混合ワクチンの販売：企業別 (2018-2023)
    • 世界の乳幼児・小児用混合ワクチンの販売市場シェア：企業別 (2018-2023)
    • 世界の上位10・上位5企業： 乳幼児・小児用混合ワクチン in 2022
  • 世界の乳幼児・小児用混合ワクチンの収益：企業別
    • 世界の乳幼児・小児用混合ワクチンの収益：企業別 (2018-2023)
    • 世界の乳幼児・小児用混合ワクチンの収益市場シェア：企業別 (2018-2023)
    • 世界の上位10・上位5企業： 乳幼児・小児用混合ワクチンの収益 2022
  • 世界の主要企業 乳幼児・小児用混合ワクチン, 業界ランキング, 2021 VS 2022 VS 2023
  • 世界の乳幼児・小児用混合ワクチンの販売価格：企業別
  • 競合情勢の分析
    • 企業の市場集中度 (CR5 and HHI)
    • 世界の乳幼児・小児用混合ワクチンの市場シェア：企業タイプ別 (Tier 1, Tier 2, and Tier 3)
  • 世界の主要メーカー 乳幼児・小児用混合ワクチン, 製造拠点分布と本社
  • 世界の主要メーカー 乳幼児・小児用混合ワクチン, 提供製品と用途
  • 世界の主要メーカー 乳幼児・小児用混合ワクチン, 業界参入時期
  • M&A, 拡張計画

第4章 市場規模：タイプ別

  • 世界の乳幼児・小児用混合ワクチンの販売：タイプ別
    • 世界の乳幼児・小児用混合ワクチンの販売実績：タイプ別 (2018-2023)
    • 世界の乳幼児・小児用混合ワクチンの販売予測：タイプ別 (2024-2029)
    • 世界の乳幼児・小児用混合ワクチンの販売市場シェア：タイプ別 (2018-2029)
  • 世界の乳幼児・小児用混合ワクチン 収益：タイプ別
    • 世界の乳幼児・小児用混合ワクチンの収益実績：タイプ別 (2018-2023)
    • 世界の乳幼児・小児用混合ワクチンの収益予測：タイプ別 (2024-2029)
    • 世界の乳幼児・小児用混合ワクチンの収益市場シェア：タイプ別 (2018-2029)
  • 世界の乳幼児・小児用混合ワクチンの価格：タイプ別
    • 世界の乳幼児・小児用混合ワクチンの価格：タイプ別 (2018-2023)
    • 世界の乳幼児・小児用混合ワクチンの価格予測：タイプ別 (2024-2029)

第5章 市場規模：用途別

  • 世界の乳幼児・小児用混合ワクチンの販売：用途別
    • 世界の乳幼児・小児用混合ワクチンの販売実績：用途別 (2018-2023)
    • 世界の乳幼児・小児用混合ワクチンの販売予測：用途別 (2024-2029)
    • 世界の乳幼児・小児用混合ワクチンの販売市場シェア：用途別 (2018-2029)
  • 世界の乳幼児・小児用混合ワクチンの収益：用途別
    • 世界の乳幼児・小児用混合ワクチンの収益実績：用途別 (2018-2023)
    • 世界の乳幼児・小児用混合ワクチンの収益予測：用途別 (2024-2029)
    • 世界の乳幼児・小児用混合ワクチンの収益市場シェア：用途別 (2018-2029)
  • 世界の乳幼児・小児用混合ワクチンの価格：用途別
    • 世界の乳幼児・小児用混合ワクチンの価格：用途別 (2018-2023)
    • 世界の乳幼児・小児用混合ワクチンの価格予測：用途別 (2024-2029)

第6章 米国・カナダ

  • 米国・カナダ 乳幼児・小児用混合ワクチン 市場規模：タイプ別
    • 米国・カナダ 乳幼児・小児用混合ワクチンの販売：タイプ別 (2018-2029)
    • 米国・カナダ 乳幼児・小児用混合ワクチン 収益：タイプ別 (2018-2029)
  • 米国・カナダ 乳幼児・小児用混合ワクチン 市場規模：用途別
    • 米国・カナダ 乳幼児・小児用混合ワクチンの販売：用途別 (2018-2029)
    • 米国・カナダ 乳幼児・小児用混合ワクチンの収益：用途別 (2018-2029)
  • 米国・カナダ 乳幼児・小児用混合ワクチン 市場規模：国別
    • 米国・カナダ 乳幼児・小児用混合ワクチンの収益：国別: 2018 VS 2022 VS 2029
    • 米国・カナダ 乳幼児・小児用混合ワクチンの販売：国別 (2018-2029)
    • 米国・カナダ 乳幼児・小児用混合ワクチンの収益：国別 (2018-2029)
    • US
    • カナダ

第7章 欧州

  • 欧州の乳幼児・小児用混合ワクチン 市場規模：タイプ別
    • 欧州の乳幼児・小児用混合ワクチンの販売：タイプ別 (2018-2029)
    • 欧州の乳幼児・小児用混合ワクチン 収益：タイプ別 (2018-2029)
  • 欧州の乳幼児・小児用混合ワクチン 市場規模：用途別
    • 欧州の乳幼児・小児用混合ワクチンの販売：用途別 (2018-2029)
    • 欧州の乳幼児・小児用混合ワクチンの収益：用途別 (2018-2029)
  • 欧州の乳幼児・小児用混合ワクチン 市場規模：国別
    • 欧州の乳幼児・小児用混合ワクチンの収益：国別: 2018 VS 2022 VS 2029
    • 欧州の乳幼児・小児用混合ワクチンの販売：国別 (2018-2029)
    • 欧州の乳幼児・小児用混合ワクチンの収益：国別 (2018-2029)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア

第8章 中国

  • 中国の乳幼児・小児用混合ワクチン 市場規模
    • 中国の乳幼児・小児用混合ワクチン 売上 (2018-2029)
    • 中国の乳幼児・小児用混合ワクチン 収益 (2018-2029)
  • 中国の乳幼児・小児用混合ワクチン 市場規模：用途別
    • 中国の乳幼児・小児用混合ワクチンの販売：用途別 (2018-2029)
    • 中国の乳幼児・小児用混合ワクチンの収益：用途別 (2018-2029)

第9章 アジア（中国を除く）

  • アジア地域 乳幼児・小児用混合ワクチン 市場規模：タイプ別
    • アジア地域 乳幼児・小児用混合ワクチンの販売：タイプ別 (2018-2029)
    • アジア地域 乳幼児・小児用混合ワクチン 収益：タイプ別 (2018-2029)
  • アジア地域 乳幼児・小児用混合ワクチン 市場規模：用途別
    • アジア地域 乳幼児・小児用混合ワクチンの販売：用途別 (2018-2029)
    • アジア地域 乳幼児・小児用混合ワクチンの収益：用途別 (2018-2029)
  • アジア地域 乳幼児・小児用混合ワクチンの販売：地域別
    • アジア地域 乳幼児・小児用混合ワクチンの収益：地域別: 2018 VS 2022 VS 2029
    • アジア地域 乳幼児・小児用混合ワクチンの収益：地域別 (2018-2029)
    • アジア地域 乳幼児・小児用混合ワクチンの販売：地域別 (2018-2029)
    • 日本
    • 韓国
    • 台湾
    • 東南アジア
    • インド

第10章 中東, アフリカ ・ラテンアメリカ

  • 中東, アフリカ ・ラテンアメリカの乳幼児・小児用混合ワクチン 市場規模：タイプ別
    • 中東, アフリカ ・ラテンアメリカの乳幼児・小児用混合ワクチンの販売：タイプ別 (2018-2029)
    • 中東, アフリカ ・ラテンアメリカの乳幼児・小児用混合ワクチン 収益：タイプ別 (2018-2029)
  • 中東, アフリカ ・ラテンアメリカの乳幼児・小児用混合ワクチン 市場規模：用途別
    • 中東, アフリカ ・ラテンアメリカの乳幼児・小児用混合ワクチンの販売：用途別 (2018-2029)
    • 中東, アフリカ ・ラテンアメリカの乳幼児・小児用混合ワクチンの収益：用途別 (2018-2029)
  • 中東, アフリカ ・ラテンアメリカの乳幼児・小児用混合ワクチンの販売：国別
    • 中東, アフリカ ・ラテンアメリカの乳幼児・小児用混合ワクチンの収益：国別: 2018 VS 2022 VS 2029
    • 中東, アフリカ ・ラテンアメリカの乳幼児・小児用混合ワクチンの収益：国別 (2018-2029)
    • 中東, アフリカ ・ラテンアメリカの乳幼児・小児用混合ワクチンの販売：国別 (2018-2029)
    • ブラジル
    • メキシコ
    • トルコ
    • イスラエル
    • 湾岸協力理事会諸国

第11章 企業プロファイル

  • Sanofi
  • GSK
  • Mitsubishi Tanabe Pharma
  • KM Biologics
  • Wuhan Institute of Biological Products
  • Walvax Biotechnology
  • Chengdu Institute of Biological Products
  • Minhai Biotechnology

第12章 業界チェーンと販売チャネルの分析

  • 乳幼児・小児用混合ワクチン 業界チェーン分析
  • 乳幼児・小児用混合ワクチン 主要原材料
    • 主要原材料
    • 原材料の主要サプライヤー
  • 乳幼児・小児用混合ワクチン 生産形態とプロセス
  • 乳幼児・小児用混合ワクチン 販売およびマーケティング
    • 乳幼児・小児用混合ワクチン 販売チャネルs
    • 乳幼児・小児用混合ワクチン 卸業者
  • 乳幼児・小児用混合ワクチン 顧客

第13章 市場動向

  • 乳幼児・小児用混合ワクチン 業界動向
  • 乳幼児・小児用混合ワクチン 市場の促進要因
  • 乳幼児・小児用混合ワクチン 市場の課題
  • 乳幼児・小児用混合ワクチン 市場の抑制要因

第14章 主な調査結果 世界の乳幼児・小児用混合ワクチンの主な市場調査結果

第15章 付録

図表

List of Tables

  • Table 1. Global Infant and Child Multiple Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
  • Table 2. Major Manufacturers of Pentavalent Vaccine
  • Table 3. Major Manufacturers of Quadruple Vaccine
  • Table 4. Major Manufacturers of Triple Vaccine
  • Table 5. Major Manufacturers of Others
  • Table 6. Global Infant and Child Multiple Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
  • Table 7. Global Infant and Child Multiple Vaccine Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 8. Global Infant and Child Multiple Vaccine Revenue by Region (2018-2023) & (US$ Million)
  • Table 9. Global Infant and Child Multiple Vaccine Revenue by Region (2024-2029) & (US$ Million)
  • Table 10. Global Infant and Child Multiple Vaccine Revenue Market Share by Region (2018-2023)
  • Table 11. Global Infant and Child Multiple Vaccine Revenue Market Share by Region (2024-2029)
  • Table 12. Global Infant and Child Multiple Vaccine Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 13. Global Infant and Child Multiple Vaccine Sales by Region (2018-2023) & (M Doses)
  • Table 14. Global Infant and Child Multiple Vaccine Sales by Region (2024-2029) & (M Doses)
  • Table 15. Global Infant and Child Multiple Vaccine Sales Market Share by Region (2018-2023)
  • Table 16. Global Infant and Child Multiple Vaccine Sales Market Share by Region (2024-2029)
  • Table 17. Global Infant and Child Multiple Vaccine Sales by Manufacturers (2018-2023) & (M Doses)
  • Table 18. Global Infant and Child Multiple Vaccine Sales Share by Manufacturers (2018-2023)
  • Table 19. Global Infant and Child Multiple Vaccine Revenue by Manufacturers (2018-2023) & (US$ Million)
  • Table 20. Global Infant and Child Multiple Vaccine Revenue Share by Manufacturers (2018-2023)
  • Table 21. Global Key Players of Infant and Child Multiple Vaccine, Industry Ranking, 2021 VS 2022 VS 2023
  • Table 22. Infant and Child Multiple Vaccine Price by Manufacturers 2018-2023 (US$/Dose)
  • Table 23. Global Infant and Child Multiple Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 24. Global Infant and Child Multiple Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Infant and Child Multiple Vaccine as of 2022)
  • Table 25. Global Key Manufacturers of Infant and Child Multiple Vaccine, Manufacturing Base Distribution and Headquarters
  • Table 26. Global Key Manufacturers of Infant and Child Multiple Vaccine, Product Offered and Application
  • Table 27. Global Key Manufacturers of Infant and Child Multiple Vaccine, Date of Enter into This Industry
  • Table 28. Mergers & Acquisitions, Expansion Plans
  • Table 29. Global Infant and Child Multiple Vaccine Sales by Type (2018-2023) & (M Doses)
  • Table 30. Global Infant and Child Multiple Vaccine Sales by Type (2024-2029) & (M Doses)
  • Table 31. Global Infant and Child Multiple Vaccine Sales Share by Type (2018-2023)
  • Table 32. Global Infant and Child Multiple Vaccine Sales Share by Type (2024-2029)
  • Table 33. Global Infant and Child Multiple Vaccine Revenue by Type (2018-2023) & (US$ Million)
  • Table 34. Global Infant and Child Multiple Vaccine Revenue by Type (2024-2029) & (US$ Million)
  • Table 35. Global Infant and Child Multiple Vaccine Revenue Share by Type (2018-2023)
  • Table 36. Global Infant and Child Multiple Vaccine Revenue Share by Type (2024-2029)
  • Table 37. Infant and Child Multiple Vaccine Price by Type (2018-2023) & (US$/Dose)
  • Table 38. Global Infant and Child Multiple Vaccine Price Forecast by Type (2024-2029) & (US$/Dose)
  • Table 39. Global Infant and Child Multiple Vaccine Sales by Application (2018-2023) & (M Doses)
  • Table 40. Global Infant and Child Multiple Vaccine Sales by Application (2024-2029) & (M Doses)
  • Table 41. Global Infant and Child Multiple Vaccine Sales Share by Application (2018-2023)
  • Table 42. Global Infant and Child Multiple Vaccine Sales Share by Application (2024-2029)
  • Table 43. Global Infant and Child Multiple Vaccine Revenue by Application (2018-2023) & (US$ Million)
  • Table 44. Global Infant and Child Multiple Vaccine Revenue by Application (2024-2029) & (US$ Million)
  • Table 45. Global Infant and Child Multiple Vaccine Revenue Share by Application (2018-2023)
  • Table 46. Global Infant and Child Multiple Vaccine Revenue Share by Application (2024-2029)
  • Table 47. Infant and Child Multiple Vaccine Price by Application (2018-2023) & (US$/Dose)
  • Table 48. Global Infant and Child Multiple Vaccine Price Forecast by Application (2024-2029) & (US$/Dose)
  • Table 49. US & Canada Infant and Child Multiple Vaccine Sales by Type (2018-2023) & (M Doses)
  • Table 50. US & Canada Infant and Child Multiple Vaccine Sales by Type (2024-2029) & (M Doses)
  • Table 51. US & Canada Infant and Child Multiple Vaccine Revenue by Type (2018-2023) & (US$ Million)
  • Table 52. US & Canada Infant and Child Multiple Vaccine Revenue by Type (2024-2029) & (US$ Million)
  • Table 53. US & Canada Infant and Child Multiple Vaccine Sales by Application (2018-2023) & (M Doses)
  • Table 54. US & Canada Infant and Child Multiple Vaccine Sales by Application (2024-2029) & (M Doses)
  • Table 55. US & Canada Infant and Child Multiple Vaccine Revenue by Application (2018-2023) & (US$ Million)
  • Table 56. US & Canada Infant and Child Multiple Vaccine Revenue by Application (2024-2029) & (US$ Million)
  • Table 57. US & Canada Infant and Child Multiple Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 58. US & Canada Infant and Child Multiple Vaccine Revenue by Country (2018-2023) & (US$ Million)
  • Table 59. US & Canada Infant and Child Multiple Vaccine Revenue by Country (2024-2029) & (US$ Million)
  • Table 60. US & Canada Infant and Child Multiple Vaccine Sales by Country (2018-2023) & (M Doses)
  • Table 61. US & Canada Infant and Child Multiple Vaccine Sales by Country (2024-2029) & (M Doses)
  • Table 62. Europe Infant and Child Multiple Vaccine Sales by Type (2018-2023) & (M Doses)
  • Table 63. Europe Infant and Child Multiple Vaccine Sales by Type (2024-2029) & (M Doses)
  • Table 64. Europe Infant and Child Multiple Vaccine Revenue by Type (2018-2023) & (US$ Million)
  • Table 65. Europe Infant and Child Multiple Vaccine Revenue by Type (2024-2029) & (US$ Million)
  • Table 66. Europe Infant and Child Multiple Vaccine Sales by Application (2018-2023) & (M Doses)
  • Table 67. Europe Infant and Child Multiple Vaccine Sales by Application (2024-2029) & (M Doses)
  • Table 68. Europe Infant and Child Multiple Vaccine Revenue by Application (2018-2023) & (US$ Million)
  • Table 69. Europe Infant and Child Multiple Vaccine Revenue by Application (2024-2029) & (US$ Million)
  • Table 70. Europe Infant and Child Multiple Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 71. Europe Infant and Child Multiple Vaccine Revenue by Country (2018-2023) & (US$ Million)
  • Table 72. Europe Infant and Child Multiple Vaccine Revenue by Country (2024-2029) & (US$ Million)
  • Table 73. Europe Infant and Child Multiple Vaccine Sales by Country (2018-2023) & (M Doses)
  • Table 74. Europe Infant and Child Multiple Vaccine Sales by Country (2024-2029) & (M Doses)
  • Table 75. China Infant and Child Multiple Vaccine Sales by Type (2018-2023) & (M Doses)
  • Table 76. China Infant and Child Multiple Vaccine Sales by Type (2024-2029) & (M Doses)
  • Table 77. China Infant and Child Multiple Vaccine Revenue by Type (2018-2023) & (US$ Million)
  • Table 78. China Infant and Child Multiple Vaccine Revenue by Type (2024-2029) & (US$ Million)
  • Table 79. China Infant and Child Multiple Vaccine Sales by Application (2018-2023) & (M Doses)
  • Table 80. China Infant and Child Multiple Vaccine Sales by Application (2024-2029) & (M Doses)
  • Table 81. China Infant and Child Multiple Vaccine Revenue by Application (2018-2023) & (US$ Million)
  • Table 82. China Infant and Child Multiple Vaccine Revenue by Application (2024-2029) & (US$ Million)
  • Table 83. Asia Infant and Child Multiple Vaccine Sales by Type (2018-2023) & (M Doses)
  • Table 84. Asia Infant and Child Multiple Vaccine Sales by Type (2024-2029) & (M Doses)
  • Table 85. Asia Infant and Child Multiple Vaccine Revenue by Type (2018-2023) & (US$ Million)
  • Table 86. Asia Infant and Child Multiple Vaccine Revenue by Type (2024-2029) & (US$ Million)
  • Table 87. Asia Infant and Child Multiple Vaccine Sales by Application (2018-2023) & (M Doses)
  • Table 88. Asia Infant and Child Multiple Vaccine Sales by Application (2024-2029) & (M Doses)
  • Table 89. Asia Infant and Child Multiple Vaccine Revenue by Application (2018-2023) & (US$ Million)
  • Table 90. Asia Infant and Child Multiple Vaccine Revenue by Application (2024-2029) & (US$ Million)
  • Table 91. Asia Infant and Child Multiple Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 92. Asia Infant and Child Multiple Vaccine Revenue by Region (2018-2023) & (US$ Million)
  • Table 93. Asia Infant and Child Multiple Vaccine Revenue by Region (2024-2029) & (US$ Million)
  • Table 94. Asia Infant and Child Multiple Vaccine Sales by Region (2018-2023) & (M Doses)
  • Table 95. Asia Infant and Child Multiple Vaccine Sales by Region (2024-2029) & (M Doses)
  • Table 96. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Sales by Type (2018-2023) & (M Doses)
  • Table 97. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Sales by Type (2024-2029) & (M Doses)
  • Table 98. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Revenue by Type (2018-2023) & (US$ Million)
  • Table 99. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Revenue by Type (2024-2029) & (US$ Million)
  • Table 100. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Sales by Application (2018-2023) & (M Doses)
  • Table 101. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Sales by Application (2024-2029) & (M Doses)
  • Table 102. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Revenue by Application (2018-2023) & (US$ Million)
  • Table 103. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Revenue by Application (2024-2029) & (US$ Million)
  • Table 104. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 105. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Revenue by Country (2018-2023) & (US$ Million)
  • Table 106. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Revenue by Country (2024-2029) & (US$ Million)
  • Table 107. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Sales by Country (2018-2023) & (M Doses)
  • Table 108. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Sales by Country (2024-2029) & (M Doses)
  • Table 109. Sanofi Company Information
  • Table 110. Sanofi Description and Major Businesses
  • Table 111. Sanofi Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)
  • Table 112. Sanofi Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 113. Sanofi Recent Developments
  • Table 114. GSK Company Information
  • Table 115. GSK Description and Major Businesses
  • Table 116. GSK Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)
  • Table 117. GSK Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 118. GSK Recent Developments
  • Table 119. Mitsubishi Tanabe Pharma Company Information
  • Table 120. Mitsubishi Tanabe Pharma Description and Major Businesses
  • Table 121. Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)
  • Table 122. Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 123. Mitsubishi Tanabe Pharma Recent Developments
  • Table 124. KM Biologics Company Information
  • Table 125. KM Biologics Description and Major Businesses
  • Table 126. KM Biologics Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)
  • Table 127. KM Biologics Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 128. KM Biologics Recent Developments
  • Table 129. Wuhan Institute of Biological Products Company Information
  • Table 130. Wuhan Institute of Biological Products Description and Major Businesses
  • Table 131. Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)
  • Table 132. Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 133. Wuhan Institute of Biological Products Recent Developments
  • Table 134. Walvax Biotechnology Company Information
  • Table 135. Walvax Biotechnology Description and Major Businesses
  • Table 136. Walvax Biotechnology Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)
  • Table 137. Walvax Biotechnology Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 138. Walvax Biotechnology Recent Developments
  • Table 139. Chengdu Institute of Biological Products Company Information
  • Table 140. Chengdu Institute of Biological Products Description and Major Businesses
  • Table 141. Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)
  • Table 142. Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 143. Chengdu Institute of Biological Products Recent Developments
  • Table 144. Minhai Biotechnology Company Information
  • Table 145. Minhai Biotechnology Description and Major Businesses
  • Table 146. Minhai Biotechnology Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)
  • Table 147. Minhai Biotechnology Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 148. Minhai Biotechnology Recent Developments
  • Table 149. Key Raw Materials Lists
  • Table 150. Raw Materials Key Suppliers Lists
  • Table 151. Infant and Child Multiple Vaccine Distributors List
  • Table 152. Infant and Child Multiple Vaccine Customers List
  • Table 153. Infant and Child Multiple Vaccine Market Trends
  • Table 154. Infant and Child Multiple Vaccine Market Drivers
  • Table 155. Infant and Child Multiple Vaccine Market Challenges
  • Table 156. Infant and Child Multiple Vaccine Market Restraints
  • Table 157. Research Programs/Design for This Report
  • Table 158. Key Data Information from Secondary Sources
  • Table 159. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Infant and Child Multiple Vaccine Product Picture
  • Figure 2. Global Infant and Child Multiple Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
  • Figure 3. Global Infant and Child Multiple Vaccine Market Share by Type in 2022 & 2029
  • Figure 4. Pentavalent Vaccine Product Picture
  • Figure 5. Quadruple Vaccine Product Picture
  • Figure 6. Triple Vaccine Product Picture
  • Figure 7. Others Product Picture
  • Figure 8. Global Infant and Child Multiple Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
  • Figure 9. Global Infant and Child Multiple Vaccine Market Share by Application in 2022 & 2029
  • Figure 10. 12 Months Below
  • Figure 11. 12 Months Above
  • Figure 12. Infant and Child Multiple Vaccine Report Years Considered
  • Figure 13. Global Infant and Child Multiple Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2029
  • Figure 14. Global Infant and Child Multiple Vaccine Revenue 2018-2029 (US$ Million)
  • Figure 15. Global Infant and Child Multiple Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2029
  • Figure 16. Global Infant and Child Multiple Vaccine Revenue Market Share by Region (2018-2029)
  • Figure 17. Global Infant and Child Multiple Vaccine Sales 2018-2029 ((M Doses)
  • Figure 18. Global Infant and Child Multiple Vaccine Sales Market Share by Region (2018-2029)
  • Figure 19. US & Canada Infant and Child Multiple Vaccine Sales YoY (2018-2029) & (M Doses)
  • Figure 20. US & Canada Infant and Child Multiple Vaccine Revenue YoY (2018-2029) & (US$ Million)
  • Figure 21. Europe Infant and Child Multiple Vaccine Sales YoY (2018-2029) & (M Doses)
  • Figure 22. Europe Infant and Child Multiple Vaccine Revenue YoY (2018-2029) & (US$ Million)
  • Figure 23. China Infant and Child Multiple Vaccine Sales YoY (2018-2029) & (M Doses)
  • Figure 24. China Infant and Child Multiple Vaccine Revenue YoY (2018-2029) & (US$ Million)
  • Figure 25. Asia (excluding China) Infant and Child Multiple Vaccine Sales YoY (2018-2029) & (M Doses)
  • Figure 26. Asia (excluding China) Infant and Child Multiple Vaccine Revenue YoY (2018-2029) & (US$ Million)
  • Figure 27. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Sales YoY (2018-2029) & (M Doses)
  • Figure 28. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Revenue YoY (2018-2029) & (US$ Million)
  • Figure 29. The Infant and Child Multiple Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
  • Figure 30. The Top 5 and 10 Largest Manufacturers of Infant and Child Multiple Vaccine in the World: Market Share by Infant and Child Multiple Vaccine Revenue in 2022
  • Figure 31. Global Infant and Child Multiple Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
  • Figure 32. Global Infant and Child Multiple Vaccine Sales Market Share by Type (2018-2029)
  • Figure 33. Global Infant and Child Multiple Vaccine Revenue Market Share by Type (2018-2029)
  • Figure 34. Global Infant and Child Multiple Vaccine Sales Market Share by Application (2018-2029)
  • Figure 35. Global Infant and Child Multiple Vaccine Revenue Market Share by Application (2018-2029)
  • Figure 36. US & Canada Infant and Child Multiple Vaccine Sales Market Share by Type (2018-2029)
  • Figure 37. US & Canada Infant and Child Multiple Vaccine Revenue Market Share by Type (2018-2029)
  • Figure 38. US & Canada Infant and Child Multiple Vaccine Sales Market Share by Application (2018-2029)
  • Figure 39. US & Canada Infant and Child Multiple Vaccine Revenue Market Share by Application (2018-2029)
  • Figure 40. US & Canada Infant and Child Multiple Vaccine Revenue Share by Country (2018-2029)
  • Figure 41. US & Canada Infant and Child Multiple Vaccine Sales Share by Country (2018-2029)
  • Figure 42. U.S. Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 43. Canada Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 44. Europe Infant and Child Multiple Vaccine Sales Market Share by Type (2018-2029)
  • Figure 45. Europe Infant and Child Multiple Vaccine Revenue Market Share by Type (2018-2029)
  • Figure 46. Europe Infant and Child Multiple Vaccine Sales Market Share by Application (2018-2029)
  • Figure 47. Europe Infant and Child Multiple Vaccine Revenue Market Share by Application (2018-2029)
  • Figure 48. Europe Infant and Child Multiple Vaccine Revenue Share by Country (2018-2029)
  • Figure 49. Europe Infant and Child Multiple Vaccine Sales Share by Country (2018-2029)
  • Figure 50. Germany Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 51. France Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 52. U.K. Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 53. Italy Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 54. Russia Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 55. China Infant and Child Multiple Vaccine Sales Market Share by Type (2018-2029)
  • Figure 56. China Infant and Child Multiple Vaccine Revenue Market Share by Type (2018-2029)
  • Figure 57. China Infant and Child Multiple Vaccine Sales Market Share by Application (2018-2029)
  • Figure 58. China Infant and Child Multiple Vaccine Revenue Market Share by Application (2018-2029)
  • Figure 59. Asia Infant and Child Multiple Vaccine Sales Market Share by Type (2018-2029)
  • Figure 60. Asia Infant and Child Multiple Vaccine Revenue Market Share by Type (2018-2029)
  • Figure 61. Asia Infant and Child Multiple Vaccine Sales Market Share by Application (2018-2029)
  • Figure 62. Asia Infant and Child Multiple Vaccine Revenue Market Share by Application (2018-2029)
  • Figure 63. Asia Infant and Child Multiple Vaccine Revenue Share by Region (2018-2029)
  • Figure 64. Asia Infant and Child Multiple Vaccine Sales Share by Region (2018-2029)
  • Figure 65. Japan Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 66. South Korea Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 67. China Taiwan Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 68. Southeast Asia Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 69. India Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 70. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Sales Market Share by Type (2018-2029)
  • Figure 71. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Revenue Market Share by Type (2018-2029)
  • Figure 72. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Sales Market Share by Application (2018-2029)
  • Figure 73. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Revenue Market Share by Application (2018-2029)
  • Figure 74. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Revenue Share by Country (2018-2029)
  • Figure 75. Middle East, Africa and Latin America Infant and Child Multiple Vaccine Sales Share by Country (2018-2029)
  • Figure 76. Brazil Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 77. Mexico Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 78. Turkey Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 79. Israel Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 80. GCC Countries Infant and Child Multiple Vaccine Revenue (2018-2029) & (US$ Million)
  • Figure 81. Infant and Child Multiple Vaccine Value Chain
  • Figure 82. Infant and Child Multiple Vaccine Production Process
  • Figure 83. Channels of Distribution
  • Figure 84. Distributors Profiles
  • Figure 85. Bottom-up and Top-down Approaches for This Report
  • Figure 86. Data Triangulation
  • Figure 87. Key Executives Interviewed
目次

This research report focuses on the Infant and Child Multiple Vaccine Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Study Coverage

  • 1.1 Infant and Child Multiple Vaccine Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global Infant and Child Multiple Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
    • 1.2.2 Pentavalent Vaccine
    • 1.2.3 Quadruple Vaccine
    • 1.2.4 Triple Vaccine
    • 1.2.5 Others
  • 1.3 Market by Application
    • 1.3.1 Global Infant and Child Multiple Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
    • 1.3.2 12 Months Below
    • 1.3.3 12 Months Above
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Executive Summary

  • 2.1 Global Infant and Child Multiple Vaccine Sales Estimates and Forecasts 2018-2029
  • 2.2 Global Infant and Child Multiple Vaccine Revenue by Region
    • 2.2.1 Global Infant and Child Multiple Vaccine Revenue by Region: 2018 VS 2022 VS 2029
    • 2.2.2 Global Infant and Child Multiple Vaccine Revenue by Region (2018-2023)
    • 2.2.3 Global Infant and Child Multiple Vaccine Revenue by Region (2024-2029)
    • 2.2.4 Global Infant and Child Multiple Vaccine Revenue Market Share by Region (2018-2029)
  • 2.3 Global Infant and Child Multiple Vaccine Sales Estimates and Forecasts 2018-2029
  • 2.4 Global Infant and Child Multiple Vaccine Sales by Region
    • 2.4.1 Global Infant and Child Multiple Vaccine Sales by Region: 2018 VS 2022 VS 2029
    • 2.4.2 Global Infant and Child Multiple Vaccine Sales by Region (2018-2023)
    • 2.4.3 Global Infant and Child Multiple Vaccine Sales by Region (2024-2029)
    • 2.4.4 Global Infant and Child Multiple Vaccine Sales Market Share by Region (2018-2029)
  • 2.5 US & Canada
  • 2.6 Europe
  • 2.7 China
  • 2.8 Asia (excluding China)
  • 2.9 Middle East, Africa and Latin America

3 Competition by Manufactures

  • 3.1 Global Infant and Child Multiple Vaccine Sales by Manufacturers
    • 3.1.1 Global Infant and Child Multiple Vaccine Sales by Manufacturers (2018-2023)
    • 3.1.2 Global Infant and Child Multiple Vaccine Sales Market Share by Manufacturers (2018-2023)
    • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Infant and Child Multiple Vaccine in 2022
  • 3.2 Global Infant and Child Multiple Vaccine Revenue by Manufacturers
    • 3.2.1 Global Infant and Child Multiple Vaccine Revenue by Manufacturers (2018-2023)
    • 3.2.2 Global Infant and Child Multiple Vaccine Revenue Market Share by Manufacturers (2018-2023)
    • 3.2.3 Global Top 10 and Top 5 Companies by Infant and Child Multiple Vaccine Revenue in 2022
  • 3.3 Global Key Players of Infant and Child Multiple Vaccine, Industry Ranking, 2021 VS 2022 VS 2023
  • 3.4 Global Infant and Child Multiple Vaccine Sales Price by Manufacturers
  • 3.5 Analysis of Competitive Landscape
    • 3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.5.2 Global Infant and Child Multiple Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.6 Global Key Manufacturers of Infant and Child Multiple Vaccine, Manufacturing Base Distribution and Headquarters
  • 3.7 Global Key Manufacturers of Infant and Child Multiple Vaccine, Product Offered and Application
  • 3.8 Global Key Manufacturers of Infant and Child Multiple Vaccine, Date of Enter into This Industry
  • 3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global Infant and Child Multiple Vaccine Sales by Type
    • 4.1.1 Global Infant and Child Multiple Vaccine Historical Sales by Type (2018-2023)
    • 4.1.2 Global Infant and Child Multiple Vaccine Forecasted Sales by Type (2024-2029)
    • 4.1.3 Global Infant and Child Multiple Vaccine Sales Market Share by Type (2018-2029)
  • 4.2 Global Infant and Child Multiple Vaccine Revenue by Type
    • 4.2.1 Global Infant and Child Multiple Vaccine Historical Revenue by Type (2018-2023)
    • 4.2.2 Global Infant and Child Multiple Vaccine Forecasted Revenue by Type (2024-2029)
    • 4.2.3 Global Infant and Child Multiple Vaccine Revenue Market Share by Type (2018-2029)
  • 4.3 Global Infant and Child Multiple Vaccine Price by Type
    • 4.3.1 Global Infant and Child Multiple Vaccine Price by Type (2018-2023)
    • 4.3.2 Global Infant and Child Multiple Vaccine Price Forecast by Type (2024-2029)

5 Market Size by Application

  • 5.1 Global Infant and Child Multiple Vaccine Sales by Application
    • 5.1.1 Global Infant and Child Multiple Vaccine Historical Sales by Application (2018-2023)
    • 5.1.2 Global Infant and Child Multiple Vaccine Forecasted Sales by Application (2024-2029)
    • 5.1.3 Global Infant and Child Multiple Vaccine Sales Market Share by Application (2018-2029)
  • 5.2 Global Infant and Child Multiple Vaccine Revenue by Application
    • 5.2.1 Global Infant and Child Multiple Vaccine Historical Revenue by Application (2018-2023)
    • 5.2.2 Global Infant and Child Multiple Vaccine Forecasted Revenue by Application (2024-2029)
    • 5.2.3 Global Infant and Child Multiple Vaccine Revenue Market Share by Application (2018-2029)
  • 5.3 Global Infant and Child Multiple Vaccine Price by Application
    • 5.3.1 Global Infant and Child Multiple Vaccine Price by Application (2018-2023)
    • 5.3.2 Global Infant and Child Multiple Vaccine Price Forecast by Application (2024-2029)

6 US & Canada

  • 6.1 US & Canada Infant and Child Multiple Vaccine Market Size by Type
    • 6.1.1 US & Canada Infant and Child Multiple Vaccine Sales by Type (2018-2029)
    • 6.1.2 US & Canada Infant and Child Multiple Vaccine Revenue by Type (2018-2029)
  • 6.2 US & Canada Infant and Child Multiple Vaccine Market Size by Application
    • 6.2.1 US & Canada Infant and Child Multiple Vaccine Sales by Application (2018-2029)
    • 6.2.2 US & Canada Infant and Child Multiple Vaccine Revenue by Application (2018-2029)
  • 6.3 US & Canada Infant and Child Multiple Vaccine Market Size by Country
    • 6.3.1 US & Canada Infant and Child Multiple Vaccine Revenue by Country: 2018 VS 2022 VS 2029
    • 6.3.2 US & Canada Infant and Child Multiple Vaccine Sales by Country (2018-2029)
    • 6.3.3 US & Canada Infant and Child Multiple Vaccine Revenue by Country (2018-2029)
    • 6.3.4 US
    • 6.3.5 Canada

7 Europe

  • 7.1 Europe Infant and Child Multiple Vaccine Market Size by Type
    • 7.1.1 Europe Infant and Child Multiple Vaccine Sales by Type (2018-2029)
    • 7.1.2 Europe Infant and Child Multiple Vaccine Revenue by Type (2018-2029)
  • 7.2 Europe Infant and Child Multiple Vaccine Market Size by Application
    • 7.2.1 Europe Infant and Child Multiple Vaccine Sales by Application (2018-2029)
    • 7.2.2 Europe Infant and Child Multiple Vaccine Revenue by Application (2018-2029)
  • 7.3 Europe Infant and Child Multiple Vaccine Market Size by Country
    • 7.3.1 Europe Infant and Child Multiple Vaccine Revenue by Country: 2018 VS 2022 VS 2029
    • 7.3.2 Europe Infant and Child Multiple Vaccine Sales by Country (2018-2029)
    • 7.3.3 Europe Infant and Child Multiple Vaccine Revenue by Country (2018-2029)
    • 7.3.4 Germany
    • 7.3.5 France
    • 7.3.6 U.K.
    • 7.3.7 Italy
    • 7.3.8 Russia

8 China

  • 8.1 China Infant and Child Multiple Vaccine Market Size
    • 8.1.1 China Infant and Child Multiple Vaccine Sales (2018-2029)
    • 8.1.2 China Infant and Child Multiple Vaccine Revenue (2018-2029)
  • 8.2 China Infant and Child Multiple Vaccine Market Size by Application
    • 8.2.1 China Infant and Child Multiple Vaccine Sales by Application (2018-2029)
    • 8.2.2 China Infant and Child Multiple Vaccine Revenue by Application (2018-2029)

9 Asia (excluding China)

  • 9.1 Asia Infant and Child Multiple Vaccine Market Size by Type
    • 9.1.1 Asia Infant and Child Multiple Vaccine Sales by Type (2018-2029)
    • 9.1.2 Asia Infant and Child Multiple Vaccine Revenue by Type (2018-2029)
  • 9.2 Asia Infant and Child Multiple Vaccine Market Size by Application
    • 9.2.1 Asia Infant and Child Multiple Vaccine Sales by Application (2018-2029)
    • 9.2.2 Asia Infant and Child Multiple Vaccine Revenue by Application (2018-2029)
  • 9.3 Asia Infant and Child Multiple Vaccine Sales by Region
    • 9.3.1 Asia Infant and Child Multiple Vaccine Revenue by Region: 2018 VS 2022 VS 2029
    • 9.3.2 Asia Infant and Child Multiple Vaccine Revenue by Region (2018-2029)
    • 9.3.3 Asia Infant and Child Multiple Vaccine Sales by Region (2018-2029)
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 China Taiwan
    • 9.3.7 Southeast Asia
    • 9.3.8 India

10 Middle East, Africa and Latin America

  • 10.1 Middle East, Africa and Latin America Infant and Child Multiple Vaccine Market Size by Type
    • 10.1.1 Middle East, Africa and Latin America Infant and Child Multiple Vaccine Sales by Type (2018-2029)
    • 10.1.2 Middle East, Africa and Latin America Infant and Child Multiple Vaccine Revenue by Type (2018-2029)
  • 10.2 Middle East, Africa and Latin America Infant and Child Multiple Vaccine Market Size by Application
    • 10.2.1 Middle East, Africa and Latin America Infant and Child Multiple Vaccine Sales by Application (2018-2029)
    • 10.2.2 Middle East, Africa and Latin America Infant and Child Multiple Vaccine Revenue by Application (2018-2029)
  • 10.3 Middle East, Africa and Latin America Infant and Child Multiple Vaccine Sales by Country
    • 10.3.1 Middle East, Africa and Latin America Infant and Child Multiple Vaccine Revenue by Country: 2018 VS 2022 VS 2029
    • 10.3.2 Middle East, Africa and Latin America Infant and Child Multiple Vaccine Revenue by Country (2018-2029)
    • 10.3.3 Middle East, Africa and Latin America Infant and Child Multiple Vaccine Sales by Country (2018-2029)
    • 10.3.4 Brazil
    • 10.3.5 Mexico
    • 10.3.6 Turkey
    • 10.3.7 Israel
    • 10.3.8 GCC Countries

11 Company Profiles

  • 11.1 Sanofi
    • 11.1.1 Sanofi Company Information
    • 11.1.2 Sanofi Overview
    • 11.1.3 Sanofi Infant and Child Multiple Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.1.4 Sanofi Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.1.5 Sanofi Recent Developments
  • 11.2 GSK
    • 11.2.1 GSK Company Information
    • 11.2.2 GSK Overview
    • 11.2.3 GSK Infant and Child Multiple Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.2.4 GSK Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.2.5 GSK Recent Developments
  • 11.3 Mitsubishi Tanabe Pharma
    • 11.3.1 Mitsubishi Tanabe Pharma Company Information
    • 11.3.2 Mitsubishi Tanabe Pharma Overview
    • 11.3.3 Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.3.4 Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.3.5 Mitsubishi Tanabe Pharma Recent Developments
  • 11.4 KM Biologics
    • 11.4.1 KM Biologics Company Information
    • 11.4.2 KM Biologics Overview
    • 11.4.3 KM Biologics Infant and Child Multiple Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.4.4 KM Biologics Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.4.5 KM Biologics Recent Developments
  • 11.5 Wuhan Institute of Biological Products
    • 11.5.1 Wuhan Institute of Biological Products Company Information
    • 11.5.2 Wuhan Institute of Biological Products Overview
    • 11.5.3 Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.5.4 Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.5.5 Wuhan Institute of Biological Products Recent Developments
  • 11.6 Walvax Biotechnology
    • 11.6.1 Walvax Biotechnology Company Information
    • 11.6.2 Walvax Biotechnology Overview
    • 11.6.3 Walvax Biotechnology Infant and Child Multiple Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.6.4 Walvax Biotechnology Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.6.5 Walvax Biotechnology Recent Developments
  • 11.7 Chengdu Institute of Biological Products
    • 11.7.1 Chengdu Institute of Biological Products Company Information
    • 11.7.2 Chengdu Institute of Biological Products Overview
    • 11.7.3 Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.7.4 Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.7.5 Chengdu Institute of Biological Products Recent Developments
  • 11.8 Minhai Biotechnology
    • 11.8.1 Minhai Biotechnology Company Information
    • 11.8.2 Minhai Biotechnology Overview
    • 11.8.3 Minhai Biotechnology Infant and Child Multiple Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.8.4 Minhai Biotechnology Infant and Child Multiple Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.8.5 Minhai Biotechnology Recent Developments

12 Industry Chain and Sales Channels Analysis

  • 12.1 Infant and Child Multiple Vaccine Industry Chain Analysis
  • 12.2 Infant and Child Multiple Vaccine Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Infant and Child Multiple Vaccine Production Mode & Process
  • 12.4 Infant and Child Multiple Vaccine Sales and Marketing
    • 12.4.1 Infant and Child Multiple Vaccine Sales Channels
    • 12.4.2 Infant and Child Multiple Vaccine Distributors
  • 12.5 Infant and Child Multiple Vaccine Customers

13 Market Dynamics

  • 13.1 Infant and Child Multiple Vaccine Industry Trends
  • 13.2 Infant and Child Multiple Vaccine Market Drivers
  • 13.3 Infant and Child Multiple Vaccine Market Challenges
  • 13.4 Infant and Child Multiple Vaccine Market Restraints

14 Key Findings in The Global Infant and Child Multiple Vaccine Study

15 Appendix

  • 15.1 Research Methodology
    • 15.1.1 Methodology/Research Approach
    • 15.1.2 Data Source
  • 15.2 Author Details
  • 15.3 Disclaimer